Immunex Corporation

Targeted Genetics Corporation

Amgen Inc.

Victor Fung

Dirk M Anderson

Kenneth H Grabstein

Charles Rauch

June R Eisenman

Ian L Aranha

Ryan K Takeya

Thomas C Reynolds

Perry C Wilkins

Edward M Atkinson, Iii

Edward M Atkinson

Nucleic acid sequences which encode biologically active ETF, expression vectors which direct the expression of ETF, ETF polypeptides, antibodies which specifically bind ETF and processes for preparing the same are disclosed. Also disclosed are methods for treating or preventing gastrointestinal diseases and HIV or HIV-associated diseases.

Method of treating cancer by administering an epithelum-derived T-cell factor

A method for producing recombinant proteins, preferably fusion proteins comprising an Fc portion of an immunoglobulin molecule, more preferably fusion proteins comprising an extracellular domain of a tumor necrosis factor receptor fused to the Fc portion of an immunoglobulin molecule, is disclosed. The method of the present invention allows a reduction of misfolding of the protein, thereby giving rise to a higher yield of the desired protein.

Method for producing recombinant proteins

Polynucleotides encoding epithelium-derived T-cell factor and uses thereof

This invention provides methods and compositions for producing high titer, substantially purified preparations of recombinant adeno-associated virus (AAV) that can be used as vectors for gene delivery. At the onset of vector production, AAV producer cells of this invention typically comprise one or more AAV packaging genes, an AAV vector comprising a heterologous (i.e. non-AAV) transgene of interest, and a helper virus such as an adenovirus. The AAV vector preparations produced are generally replication incompetent but are capable of mediating delivery of a transgene of interest (such as a therapeutic gene) to any of a wide variety of tissues and cells. The AAV vector preparations produced according to this invention are also substantially free of helper virus as well as helper viral and cellular proteins and other contaminants. The invention described herein provides methods of producing rAAV particles by culturing producer cells under conditions, such as temperature and pH, that promote release of virus. Also provided is a quantitative, high-throughput assay useful in the assessment of viral infectivity and replication, as well as in the screening of agent that affect viral infectivity and/or replication.

Methods for generating high titer helper-free preparations of released recombinant AAV vectors

Antibodies to epithelium-derived T-cell factor

Nucleic acid sequences which encode biologically active EMF, expression vectors which direct the expression of ETF, ETE polypeptides, antibodies which specffically bind ETF and processes for preparing the same are disclosed. Also disclosed are methods for treating or preventing gastrointestinal diseases and HIV or HIV-associated diseases.

Method of treatment with epithelium derived T-cell factor

Epithelium-derived T-cell factor antibodies

Method for treating or preventing gastrointestinal disease with

Epithelium-derived T-cell factor

There is disclosed a mammalian epithelium-derived T-cell factor (EFT) polypeptide, derivatives thereof, DNA sequences, recombinant DNA molecules and transformed host cells that produce ETF polypeptides. More particularly, this invention provides isolated mammalian ETF polypeptides and derivatives thereof that regulate events in T-lymphocyte proliferation.

DNA encoding epithelium-derived T-cell factor

Growing community of inventors

Redmond, WA, United States of America

Victor Fung